Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Julie Di Paolo"'
Autor:
Emma Rousseau, Roy Bannister, Kevin S. Currie, Jiyun Kim, Astrid S. Clarke, Kelly Wang, Julie Di Paolo, Franziska Matzkies, Bernard P. Murray
Publikováno v:
Thrombosis Research. 170:109-118
Introduction Spleen tyrosine kinase (SYK) mediates signal transduction in multiple hematopoietic cells, including platelets. SYK signals downstream of immunoreceptors and SYK inhibition may ameliorate disease pathology in multiple autoimmune disorder
Autor:
Eric B. Lansdon, Helen Yu, Kropf Jeffrey E, Peter A. Blomgren, Jennifer R. Lo, Guoju Geng, Kevin S. Currie, Aaron C. Schmitt, Jayaraman Chandrasekhar, Chris Pohlmeyer, Scott A. Mitchell, Seung H. Lee, Wanchi Fung, Sarah Wise, Jin-Ming Xiong, Zhongdong Zhao, Randall Mark Jones, Kimberly Suekawa-Pirrone, Julie Di Paolo, Bernard P. Murray, Carmen Ip, Jianjun Xu
Publikováno v:
ACS Med Chem Lett
[Image: see text] Spleen tyrosine kinase (SYK) is a critical regulator of signaling in a variety of immune cell types such as B-cells, monocytes, and macrophages. Accordingly, there have been numerous efforts to identify compounds that selectively in
Publikováno v:
Poster Presentations.
Background Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway has demonstrated efficacy in immune-mediated diseases and has been identified as a therapeutic target for the treatment of rheumatoid arth
Publikováno v:
Poster Presentations.
Background: Despite improved therapy, rheumatoid arthritis (RA) remains an area of unmet medical need. Current therapies have improved disease control by targeting inflammatory pathways. However, treatments rarely induce remission, highlighting the n
Autor:
Jiyun Kim, Alan Kivitz, Sean Hsueh, Lin Liu, John S. Sundy, Franziska Matzkies, Neelufar Mozaffarian, Daksha Mehta, Afsaneh Mozaffarian, Wendy Jiang, Mark C. Genovese, Julie Di Paolo, Rebecca Kunder
Publikováno v:
Poster Presentations.
Background Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling and is essential in activation of cells including B lymphocytes, monocytes, macrophages, dendritic cells, and osteoclasts. SYK may play an important role in the initiation and
Autor:
James J. Crawford, Joseph W. Lubach, Peter Blomgren, Pat Maciejewski, Steve Gallion, Jen Macaluso, Julie Di Paolo, Donna Dambach, Adam R. Johnson, Christine Yu, Xiaojing Wang, James Barbosa, Jin-Ming Xiong, Karin Reif, Zhongdong Zhao, Harvey Wong, Aaron C. Schmitt, Kevin S. Currie, Wendy B. Young, Kropf Jeffrey E, Scott A. Mitchell, Heleen Scheerens, Seung H. Lee, Charles Eigenbrot, Meire Bremer, Daniel F. Ortwine, Jianjun Xu, Lichuan Liu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:575-579
BTK inhibitor GDC-0834 (1) was found to be rapidly metabolized in human studies, resulting in a suspension of clinical trials. The primary route of metabolism was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiop
Publikováno v:
Gastroenterology. 158:S-1212
Autor:
Aaron C. Schmitt, Donna Dambach, Jen Macaluso, Kevin S. Currie, Xiaojing Wang, James Barbosa, Sarah G. Hymowitz, Kropf Jeffrey E, Steve Gallion, Peter Blomgren, Lichuan Liu, Scott A. Mitchell, Julie Di Paolo, Jin-Ming Xiong, Joseph W. Lubach, Pat Maciejewski, C. Gregory Sowell, Heleen Scheerens, Seung H. Lee, Karin Reif, Zhongdong Zhao, Wendy B. Young, Jianjun Xu, Harvey Wong, Brigitte Maurer, Daniel F. Ortwine, James J. Crawford, Meire Bremer
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25(6):1333-1337
SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, b
Autor:
Yingjie Han, Julie Di Paolo, Frank Y. Ma, John Kanellis, Greg H. Tesch, Sharmila Ramessur Chandran, William R. Mulley, David J. Nikolic-Paterson
Publikováno v:
Transplantation. 101(8)
Background Organ transplantation into sensitized patients with preexisting donor-specific antibodies (DSA) is very challenging. Spleen tyrosine kinase (Syk) promotes leukocyte recruitment and activation via signaling through various cell surface rece
Autor:
J. Andrew Whitney, Kevin S. Currie, Deborah Maclin, James Barbosa, Kropf Jeffrey E, Ann Marie Rossi, Eric B. Lansdon, Jennifer Macaluso, Scott A. Mitchell, Hong Rong, Tony Lee, Jianjun Xu, Steve Gallion, Patricia Maciejewski, Julie Di Paolo, Peter A. Blomgren, Zhongdong Zhao
Publikováno v:
Journal of Medicinal Chemistry. 57:3856-3873
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indica